top of page

Psilocybin Study in Nature Neuroscience Splits Brain Rewiring from Trip

Writer: Eva Pirolli
Eva Pirolli
2 minutes ago
4 min read

Separating psilocybin's rewiring of the brain from its trip gives developers of non-hallucinogenic drugs a target just as trip-based therapy nears approval, and sets up a clinical test of whether the trip matters.


Too long to read? Go for the highlights below.


  • A UC Santa Cruz team reports in mice that psilocybin's synapse-building effect and its hallucination proxy run through different cell pathways.

  • Restoring one serotonin receptor only in layer 5 cortical neurons was enough for new connections to form without the head-twitch response, while deleting it did the reverse.

  • The result supports developers of non-hallucinogenic drugs, among them Delix, which has raised $100m and expects a Phase II trial in the first half of 2027.



Researchers at the University of California, Santa Cruz have shown in mice that psilocybin's growth of new neural connections can be separated from the behaviour used as a proxy for hallucination, a peer-reviewed paper in Nature Neuroscience finds. The result lands as the first psilocybin approvals approach. It gives makers of non-hallucinogenic drugs a mechanism to build on, while leaving open whether patients benefit from the trip itself.


How the psilocybin mouse study worked


The team, led by molecular biologist Yi Zuo, used two-photon microscopy, which images individual cells in living brain tissue, to track dendritic spines, the small protrusions where neurons receive signals from their neighbours. New spines appeared in substantial numbers within 24 hours of a psilocybin dose, and many matured into mushroom-shaped structures. In mice put under chronic stress, a rough model of depression, psilocybin increased new spine formation particularly strongly and stopped the loss of existing connections. In unstressed mice it sped up both the formation of new spines and the clearing of old ones.


Credits: Angela Shang
Credits: Angela Shang

The separation came from genetic manipulation of the serotonin 2A receptor, the docking site through which psilocybin acts. When the receptor was restored only in layer 5 pyramidal neurons, psilocybin triggered new synapse formation without the head-twitch response, a rodent movement used to gauge hallucinogenic activity. Deleting the receptor from those neurons prevented structural growth and left the head twitch intact.


How non-hallucinogenic drug developers compare


The commercial question behind the paper is already being funded. Delix Therapeutics, a US spinout from the University of California, Davis, closed a $100m Series C to take its zalsupindole candidate into Phase II, which it expects to start in the first half of 2027 in recurrent major depressive disorder, with at-home dosing. The company reports a mean reduction of about 50 per cent in depression scores at day eight of a Phase Ib trial, maintained through day 36, and no hallucinogenic or similar effects among more than 120 participants studied so far.


UC Santa Cruz separates psilocybin's rewiring from its trip in mice; Delix has $100m
Credits: Delix Therapeutics

A different bet sits with Gilgamesh Pharmaceuticals, which shortened the trip rather than removing it. AbbVie bought its bretisilocin in a deal worth up to $1.2bn, after a Phase IIa in which a single 10mg dose cut depression scores by 21.6 points at day 14, against 12.1 points in the control group. At the trip-based end, Compass Pathways, the London-based psilocybin developer, completed its new drug application on 9 November, following its first Phase 3 psilocybin readout. Usona Institute, a US non-profit, has reportedly completed its own filing for major depressive disorder, Psychedelic Alpha reported, though Usona has not commented.


Taken together, the field is splitting into three bets: supervised trips, shorter trips and no trip. The Santa Cruz paper strengthens the logic of the third without validating any single compound.


What the mouse data cannot yet show


The study is careful mechanism work, because the same receptor in the same neurons was necessary for structural plasticity and dispensable for the head twitch, a tighter separation than comparing two drugs would give. Zuo describes the study as "a promising blueprint for designing nonhallucinogenic drug analogs." The experiments used engineered mice in which the receptor was restored or removed in one cell type, so a medicine would need to reproduce that selectivity through chemistry, and the head twitch remains a proxy rather than a measure of human experience. The authors' own next steps are to isolate the cells behind the hallucination-like response and to chart spine changes against mood-related behaviour.


UC Santa Cruz separates psilocybin's rewiring from its trip in mice; Delix has $100m
Credits: Richard James Harvis

Whether the trip matters is itself unsettled. A 2024 scoping review in Frontiers in Psychiatry sets out two camps: Yaden argues subjective experiences are necessary, citing psilocybin-occasioned mystical experiences in tobacco addiction, while David Olson argues that non-hallucinogenic compounds with antidepressant effects show they are not. Olson co-founded Delix, which is worth bearing in mind when weighing the company's data. Human work on network-level effects, such as a preprint on psychedelics and brain network gateways, and earlier coverage of shared brain mechanisms with standard antidepressants, suggest that spine counts in mice capture only part of the picture.


What approvals could mean next


The calendar is crowded. Compass expects a potential US launch in the first half of 2027, subject to regulatory approval and DEA rescheduling, because psilocybin remains a federally controlled substance, and the FDA's priority voucher aims for a decision within one or two months. Delix's Phase II is due to start in the same half-year, so the first human data on a compound built to avoid the trip would arrive while the first trip-based therapies are reaching patients.


If psilocybin therapy reaches the market in 2027, it will set a benchmark that tripless candidates must beat on simplicity, safety or durability, and the Santa Cruz result gives their developers a cell-level argument for why they might. AbbVie's purchase of bretisilocin offers a template for what follows, with larger drugmakers likely to buy into whichever route, shorter trips or none, first shows human efficacy, which would concentrate the field around a handful of owners.








bottom of page